GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Cyclically Adjusted PS Ratio

Accustem Sciences (Accustem Sciences) Cyclically Adjusted PS Ratio : (As of May. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Cyclically Adjusted PS Ratio?

Accustem Sciences does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Accustem Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Accustem Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Cyclically Adjusted PS Ratio Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23
Cyclically Adjusted PS Ratio
- -

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Accustem Sciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Accustem Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accustem Sciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Cyclically Adjusted PS Ratio falls into.



Accustem Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Accustem Sciences does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Accustem Sciences  (OTCPK:ACUT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Accustem Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences (Accustem Sciences) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.